GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified. See what to expect from GSK's Q3.

An mRNA vaccine, a cousin to the COVID vaccines that blunted the pandemic, has entered human trials as a treatment for lung ...

According to an infectious disease expert, Hong Kong’s flu season is expected to start in December; it is likely to have two ...

The CDC is moving toward a risk-based strategy, allowing patient input as to the frequency of COVID-19 vaccine boosters.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Moderna shares rebound after six days of losses. Analysts mixed on stock with Strong Sell rating but potential for future growth.

The 2024-2025 COVID-19 vaccines are available, and the CDC recommends that adults over 65 and immunocompromised people get ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

We expect BioNTech SE BNTX to surpass expectations when it reports third-quarter 2024 results on Nov. 4, before the opening ...

A single COVID-19 mRNA vaccine dose provided similar protection to that conferred by a 2-dose series among immunocompetent patients aged 5 years and older.

Imagine a world where the fear of paralysis loomed over every childhood summer. The smell of chlorine at the public poo ...